News

The collaboration will focus on metabolomics to develop and test new hardware and software approaches for metabolite detection and identification for environmental and clinical research. The research agreement

The new facility is expected to possess an initial capacity of 90 million units per year in addition to possible expansion of approximately 150 million units. Operations at

As per the agreement, Clinigen will manufacture, register, distribute, and commercialize the product in countries where current marketing authorizations exist, including key European, Asian and Latin American territories.

Bosulif is authorized in Europe for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) who

The 3500xL Dx is an automated 24 capillary-based Sanger Sequencer designed to deliver high quality performance, higher throughput and increased productivity for clinical laboratories around the world. The

Tecfidera reduces relapses and development of brain lesions, to slow disability progression over time. The FDA approval of Tecfidera was based on two global phase 3 studies, DEFINE

The 18,000m² facility earlier obtained manufacturing approval and cGMP certification from the RP Tuebingen, Germany. Vetter managing director Thomas Otto said, "We at Vetter work diligently to meet

The approval was based on positive data from multicenter, double-blind trial conducted in 127 pediatric patients between one to 11 years of age with GERD. Eisai president and

On 15 July 2011, the US Food and Drug Administration (FDA) had approved the product. As part of the agreement, Aptalis will produce and supply the product to